• Overview
  • Eligibility
  • More info
  • Locations

A Multi-Center Adjuvant Trial of Outpatient Moderate-Dose Bolus Interleukin-2 for Renal Cancer (NCT00003604)

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients with stage III or stage IV kidney cancer that has been removed by surgery.
  • Biological: aldesleukin
    Ages eligible for Study
    Genders eligible for Study
    Accepts Healthy Volunteers
    OBJECTIVES: I. Determine the disease free survival and overall survival of patients with resected stage III or IV renal cancer treated with interleukin-2. II. Measure the degree of rebound lymphocytosis generated by this regimen in these patients.

    OUTLINE: This is an open label study. Patients receive interleukin-2 IV over 15-30 minutes on 3 consecutive days weekly for 6 weeks, followed by 2 weeks of rest. Patients receive 2 treatment courses, each 8 weeks in duration. Patients are followed every 6 months until death.

    PROJECTED ACCRUAL: A total of 20 patients will be accrued within 1 to 2 years.

    3 locations

    United States (3)
    • Cancer Care Center for Southern Indiana
      Not specified
      Bloomington, Indiana, United States, 47403
    • Bergan Mercy Medical Center
      Not specified
      Omaha, Nebraska, United States, 68124
    • Baptist Regional Cancer Center - Knoxville
      Not specified
      Knoxville, Tennessee, United States, 37901
    30 September, 1997
    04 November, 2013
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!